BRIEF—Tavneos recommended by NICE for treatment of AAV

The UK's National Institute for Health and Care Excellence (NICE) has recommended CSL Vifor's Tavneos (avacopan), in combination with a rituximab or cyclophosphamide regimen, for the treatment of adults with the two main forms of ANCA-associated vasculitis.

The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.

The MHRA approval and the NICE recommendation were based on positive results from the Phase III ADVOCATE trial. The product is expected to launch in the UK imminently.

CSL Vifor, formerly known as Vifor Pharma, is a Swiss drugmaker now part of Australia's CSL Limited (ASX: CSL), following its $11.7 billion acquisition earlier in the year.